A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.
This is a phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 administered intravenously in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene. Study completion marks the end of the open label extension period following the 96-week blinded portion of the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
119
Evaluation of efficacy of AL001 as measured by the CDR® plus NACC FTLD-SB
The Clinical Dementia Rating Dementia Staging Instrument PLUS National Alzheimer's Disease Coordinating Center frontotemporal lobar degeneration Behavior \& Language Domains Sum of Boxes (CDR® plus NACC FTLD-SB) is administered by a healthcare professional and based on individual ratings of the eight domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, personal care, language and behavior. Impairment is scored on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2 and severe = 3. The 8 individual domain ratings, or "box scores", were added together to give the CDR® plus NACC FTLD-SB which ranges from 0-24. Higher score indicates severe impairment.
Time frame: Through study completion, on average up to 96 weeks
Change in Clinical Global Impression-Severity (CGI-S) Score
The CGI-S is used by a clinician to rate the severity of a participant's disease relative to the clinician's past experience with patients who have the same disease using an ordinal scale ranging from 1=normal, not at all ill; 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill patients. Higher scores indicate worsening.
Time frame: Baseline to 96 weeks
Change in Clinical Global Impression-Improvement (CGI-I) Score
The CGI-I is used by a clinician to rate how much a participant's disease has improved or worsened relative to baseline using an ordinal scale ranging from 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; and 7=very much worse. Higher scores indicate worsening.
Time frame: Baseline to 96 weeks
Change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score
RBANS is 20 to 25 minute battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that measure following 5 indices: (1)Attention Index, composed of Digit Span and Coding; (2)Language Index, consisting of Picture Naming and Semantic Fluency subtests; (3)Visuospatial/Construction Index, made up of Figure Copy and Line Orientation subtests; (4)Immediate Memory Index, composed of List Learning and Story Memory subtests, and (5)Delayed Memory Index, consisting of List Recall, List Recognition, Story Recall, and Figure Recall subtests. Completion of RBANS yields 5 index scores based on participant performance on various subtests, as well as a composite Total Index score for battery. Total index scores range from 40 to 160, and are normalized to a mean of 100 and standard deviation (SD) of 15. Higher scores indicate less impairment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dignity Health
Phoenix, Arizona, United States
University of California San Diego
La Jolla, California, United States
University of Colorado
Aurora, Colorado, United States
Emory University
Atlanta, Georgia, United States
Indiana University Health Neuroscience Center
Indianapolis, Indiana, United States
University of Kansas Alzheimer's Disease Center
Fairway, Kansas, United States
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Mayo Comprehensive Cancer Center - PPDS
Rochester, Minnesota, United States
Irving Institute for Clinical and Translational Research
New York, New York, United States
University Of Cincinnati Gardner Neuroscience institute
Cincinnati, Ohio, United States
...and 34 more locations
Time frame: Baseline to 96 weeks
Pharmacodynamic Biomarkers
Change in magnetic resonance imaging and blood-based biomarkers and optional CSF biomarkers (neurofilament light chain and progranulin)
Time frame: Baseline to 96 weeks
Evaluation of safety and tolerability of AL001: Incidence of adverse events
Incidence of adverse events
Time frame: Baseline to 96 weeks